Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of HS-20106 in anemia associated with lower-risk myelodysplastic syndromes
CTR20242732Phase 2Active
- Sponsor
- Keros Therapeutics
- Start
- Dec 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of elritercept in myelodysplastic syndrome (MDS), sponsored by Keros Therapeutics. Started Dec 2024; status: active.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20242732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242732.